GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.
Finding Inner Peace: Contemplative Meditation for Alzheimer's Caregivers
Caring for a loved one with Alzheimer's disease can be an emotionally and physically exhausting journey. The constant demands, coupled with the heartbreak of witnessing the gradual decline of a once-familiar person, can take a significant toll on caregivers' well-being.
The Role of Government in Fostering a Thriving Entrepreneurial Environment for Drug Research and Development
The United States government plays a pivotal role in shaping the landscape for drug research and development (R&D), fostering an environment where entrepreneurial endeavors can flourish. This blog post delves into the multifaceted ways in which the government contributes to this ecosystem, drawing insights from authoritative sources and expert opinions.
Caregivers and Mental Health: The Unsung Heroes Need Support Too
Caregiving is an act of profound love and dedication, but it can also be a challenging journey filled with emotional, physical, and mental strain.
Combating Alzheimer's: Current Treatments and Promising Pipeline Drugs
Alzheimer's disease is a devastating neurodegenerative disorder that affects millions worldwide. As the global population ages, the prevalence of Alzheimer's and related dementias is expected to rise significantly.
A Son's Reflections on Caring for His Dying Mother by Corey Hubbard
When I first became a caregiver for my terminally ill mother, I was thrust into a world I was wholly unprepared for. The woman who had always been my pillar of strength, my source of unwavering support, was now vulnerable and dependent on me.
Eliminating Bias in Pre-Screening: How Agentic AI Parses Unstructured EHR Notes for Alzheimer’s Research
Discover how Glassbury AI’s agentic architecture and zero-text FHIR mapping help biopharma sponsors achieve FDA Diversity Action Plan (DAP) compliance and eliminate Alzheimer’s trial screen failures.
The Regulatory Shift: Why Diversity Is Now a Technical Requirement
Discover how Glassbury AI’s agentic NLP platform, SYCQ 1.0, solves the FDA Diversity Action Plan (DAP) mandate and accelerates Phase III Alzheimer’s clinical trial matching.
AI Meets the Genome: The September 2026 Breakthroughs Decoding Alzheimer’s
Discover how AI models analyzing structural 3D genome folding and speech biometrics published in mid-September 2026 are cracking Alzheimer's mysteries.
Beyond Plaques & Tangles: The Brand-New Genomic & Micro-Wiring Discoveries Reshaping Alzheimer’s
Explore brand-new September 2026 breakthroughs in Alzheimer's research, from Salk's hidden microproteins to 3D genome folding and protective brain wiring.
Beyond Clearing Trash: Blocking the IDOL Enzyme Could Revolutionize Alzheimer's Care
Indiana University researchers have discovered that blocking the IDOL enzyme in neurons doesn't just clear toxic Alzheimer's plaques—it also lowers genetic risk (APOE4) and builds cognitive resilience. Read on to learn how this discovery could pave the way for a revolutionary new pill.
FDA Clears Elecsys pTau217 Blood Test: A Game-Changer for Alzheimer's Diagnosis
The FDA has cleared the Elecsys pTau217 blood test for Alzheimer's. Discover how this single-biomarker assay boosts primary care diagnostic accuracy from 65% to 93%.
The Dawn of a New Era in Alzheimer’s Care: From Simple Blood Tests to At-Home Treatments
Discover how the new p-tau217 blood test and the LEQEMBI IQLIK® autoinjector are revolutionizing Alzheimer's diagnosis and treatment at home.
The Real Cost of Memory Loss: Caregivers and Clinical Trial Diversity Matter
Learn about the true economic and social impact of Alzheimer's, the burden on unpaid caregivers, and why diversity in medical research is key to a cure.
Alzheimer’s Breakthrough: Why Tau-Targeting Therapies Are Changing the Game
Explore how tau-targeting drug Diranersen and a newly diversified research pipeline are reshaping Alzheimer's treatment and slowing cognitive decline.
Alzheimer’s Breakthroughs: Atypical Variants and New Pathways
Discover how modern neurology is moving beyond amyloid to tackle atypical Alzheimer’s variants, neuroinflammation, and systemic factors for personalized care.
Why Anti-Amyloid Alzheimer's Treatments Need a Lifestyle Boost
Discover why new Alzheimer's antibody treatments like lecanemab aren't enough on their own and why daily habits like exercise and diet play a critical role in brain health.
Introduction: Is Fish Really the Ultimate "Brain Food"?
A study published in the American Journal of Epidemiology (August 2026) addressed this question. Researchers tracked cognitively healthy older adults over a 21-year period to evaluate how consistent, sustained fish consumption influences the long-term risk of developing Alzheimer's disease.
Heart Health and Brain Shrinkage: Why Your Pulse Matters for Your Mind
We often think of the heart and the brain as two separate systems—the pump and the computer. However, a groundbreaking study from Vanderbilt University Medical Center, recently highlighted in the journal Alzheimer's & Dementia, suggests that these two organs are more closely linked than we ever imagined.
AI Revolution: Decoding Alzheimer’s Before Symptoms Start
For decades, we’ve treated Alzheimer’s like a collapsing building. We usually don’t call the engineers until the roof is already caving in—when memory loss is so severe that it disrupts daily life. The medical criteria from 1984, which set the standard for diagnosis for a long time, were built on this "end-stage" philosophy. By the time we diagnosed the disease, the damage was often irreparable.
Why Trust is the Missing Ingredient in Medical Research
For decades, the world of medical research has faced a quiet but massive problem: most clinical trials don't look like the real world. While science moves faster than ever, the way we find people to participate in life-saving studies is stuck in the past. This is especially true for underrepresented communities—including Black, Hispanic, and Asian Americans